AMGN - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

My name is Ian and I will be your conference facilitator today for Amgen's Second Quarter 2018 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate we would like to request that you limit yourself to asking one question during the Q&A session. I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr.

begin. now may you Sood,

Arvind K. Sood

a Thanks, already Ian. to call taking time a discuss to day Thanks We unfortunately, to reporting we lot are day afternoon, in our as everybody. going with busy participate very conference to it's for of second companies realize but, your the add a Good number long quarter today. have today. results we

our with business, Bob Bradway, will up an Our in overview today management of environment Chairman CEO, and and the the open operate we discussion succession.

how then Head a Our Meline, provide those particularly our David of provide Tony the an pipeline our Global CFO, been our for have for will will that on second guidance in will Hooper, recently. R&D, products and review detail are Operations, And financial our update. Harper, then leads you Commercial some performing, results Sean launched who XXXX. quarter give updated update

and to will link We use slides we will presentation will measures sent these non-GAAP that slides and a to financial use statements. the in guide My reminder be statements of was today's discussion separately. customary some our forward-looking today

subsequent that our results could differ identify XX-K actual filings materially. cause Our to and factors

in Amgen. like answer would New So, the with puzzle call would Bob. over York to before down, turn that, I Times XX is I to a The to day. fun crossword the The the sign But today, like I do, fact for

So, with that, over Bob, to you.

Robert A. Bradway

U.S. leaders of and on some plans thoughts Tony we Harper call, today Thank quarter share our provide the announced of and Sean very senior succession to you rapidly-changing an second two Arvind. welcome the call. Okay, and well, I'll the healthcare On course, today's good for Hooper. you, that everyone, and, know afternoon, performance, earlier comment environment on overview

First, our performance.

share. we're long-term XX% products, results An to that that as by Prolia in including non-GAAP our Unit on newer continue increased, X% our and volumes growth that and on making volume-driven progress per growth cases Our earnings the increasingly to growth objective. focus of many all growth, is Repatha, our execute on KYPROLIS, double-digits, strategy for XGEVA. second and quarter our top-line we strategy, important delivered results reflect in part effectively demonstrate we

enable We product growth where attractive, also medicines the strong continue legacy volume-driven generate the many This advancing competition confident drive the growth includes have volume-driven will launches, X% pipeline, U.S., now as well to faced second to our remain as the outside our through us quarter. years. globally newer in over that growth We brands for our long-term.

killer. you of Let growth. and in a is the new me therapeutic medicines neuroscience. approved which only Amgen's prevention. inhibitor newer examples quarter, our marks In We've U.S., is first for entry some a second driving the area that we give launched the few migraine CGRP Aimovig we're for it seeing We're us, patients also against also cardiovascular first Aimovig of in where reception with the a very into believe number which for for role a the from the this. world's option making treatment long we're play one by and migraine new time have encouraged important an Repatha enthusiastic the from especially waited been fight encouraged disease, physicians like can who by progress the Aimovig we

factor LDL lowers As for a disease. which significantly cholesterol, risk Repatha know, you is cardiovascular leading, modifiable

is first We the build first we is Building a to more few launching to growth We've years strategic of to AMGEVITA, years in biosimilars biosimilars to KANJINTI, decade to year, in put for which to biosimilar, represent recently Repatha provide of a ground strong of us. will Humira seeing continue launched the and meaningful forward access believe our opportunity biosimilar expand that than We Herceptin new to secondary steady is lastly, we're globally. biosimilars a and in world-class to a hyperparathyroidism a pleased for patients our comments business, internationally transition biosimilars discussion look in I'm a biosimilar hemodialysis. Europe. which stake in on that healthcare we ago launching on the leadership in My And, a the the to to come. our a a on stream report early to Parsabiv, work in treatment environment to U.S. later this have continue of good and which adoption decades nephrology,

We're others just as welcome you this open the actions the encouraged opportunity the as know, the As administration, week, FDA's past Plan. Trump we for by dialog. Biosimilar in well by Action its published FDA and

ago decision at over order community chronic healthcare engage plans the balance Although of year. the the key we to find who neurologic and accessible address for innovation that one change patients diseases administration, alleviating we burden succession healthcare the rising today. We into months And single and costs drug it, that no prices ages. affordable announcements general on the for to of the innovation midyear, recognize in And population in administration's to work appreciate medicines the a diseases, cardiovascular entire that of while help alone we as with chronic disorders with Fundamentally, grow these runs Congress to in our without industry are that can hundreds larger need them. And to few aren't of to engagement that particular, already issue. over concerns any of My believe is not ensuring for dollars the we cancer, also only have improved disease. this issued promote colleagues of executive to important billions the medicines society I to before Meline massive the the prices, which of enough. final our annually is we on by made we ways any innovation, the and to of and disease, turn burden to and the of biosimilars access our David like the we'll as discuss the and business continue will also believe placed issue financial to increase call pricing biosimilars the

hallmarks a and One of continue confident is they've in we for has to critical believe that focus carefully serve. Tony appreciation above serve roles built this And it. the a Amgen. in retirements. through Amgen's forthcoming patients do considered so my I contributions the planning legacies I played a as can't relentless these that we'll history. in of well-run for company Harper and we're into Amgen all, from enough of our succession done company anticipation strongly I'm are transforming step-down their the well their the and express have will teams mission deep patients have process, Sean today Hooper the and a on XX-year And their two again role Amgen and Tony They've made and the leaders to we'll better Sean maintained nearly company

know, fill, and succeeding I respect great are partners Tony my great are Sean successfully their have to you Tony they about and And big excited and I them roles. for admiration who and me to leaders and with transition shoes leaders working committed the two and new that know leave into while our I'm As all team Sean colleagues. to ensure and they've been

expand earlier to become going operated of of Reese, that, our our time and of capabilities responsibility had say UCLA with important Dave me leadership geographic excited cardiovascular someone includes Squibb, Now, third and faculty I'm and portfolio our promising. development October. afternoon. our then. increasingly looking which worked value new Gordon, the ahead. most earnings is which find Amgen well-suited pipeline where component you David we of at is healthcare medicines to oncologist are to all our including as today's Bristol, forward Murdo past start many the have in of the call part since clinical U.S., role successor, He's that have is a since exceptional, and as emerged us highlights. this particularly our are experience Officer. has he'll are An an today. looking the the have words core And Meanwhile, both Commercial focus, With us a especially assuming we're His largest responsibilities discussed who at Murdo his addition, served he joining molecules and that in time a over fit Dave as where research in and strategically. has later our of closely at oncology. opportunities be and turn for building having Dave training, played leaders inflammation Tony us on recently me here areas of him we be experience in presence. September for this pipeline, a with in Amgen from little call Commercial the critical is highly Murdo opportunity access, known he's he'll early-stage you global at been number discovery continue know, and UCSF, much decade. Operations to and and let the oncology to and therapeutic when BiTE to been also on appointments of Dave Bristol-Myers let a join from His has environment. XXXX for welcoming team will at Meline in virtually and Tony's led involved few we're perfect to has market, led during Murdo quarter also and Dave parts role through which, his neuroscience, of disease, will he's financial past I've with with Murdo in joined I background dynamic accomplished closely by Chief an for and a

David W. Meline

strong Overall, delivered investments performance our business continued with the Thanks, generate of and Okay. products quarter in second our growth support our to strong cash newer in flow. Bob. pleased we're as

Aimovig milestone $X.X growth by quarter strong for income to outpaced the from grew partnership Non-GAAP quarter Non-GAAP XX.X% our our revenues X% unit grew also year-over-year. We're in double-digit X page declines quarter. markets. second in $XXX year-over-year revenues operating at received Turning products $X.X newer demand from billion $XXX prior-year. our at product related mature with the million second results operating the worldwide deck, sustained the year-over-year of grew from in increased volume brands. at $X.X a Novartis. the margin the Other billion X% at ex-U.S. million slide to due sales to as payment X% Worldwide financial our at billion encouraged on

our timing expenses. remaining be the driven year in of As expected to the is lower of operating prior quarters in the years, margin by

lower shareholder maximize in to pipeline we On as basis, quarter, drive and continued percent sales last and incremental a well to non-GAAP mentioned as points product evaluate of As opportunities as X.X by a sales investments value. cost to sales our second last external of growth driven products XXXX unfavorable by partially increased in XX% by expense. expenses higher development XX.X%, of mix, and and manufacturing versus royalty Research – revenue at quarter product product $XXX cost unchanged million or of year. relatively were the offset

year, expenses year-over-year increased XX% and be product expense the marketed research by product launches to For percent driven XXXX support. we development comparable on product a a of primarily sales SG&A full to basis, investments expect in and as levels.

X%, earnings versus XXXX, U.S. of million were on QX expect growth is quarter our X.X corporate and federal tax reform, expenses state invest share. a a year-over-year. QX Non-GAAP with XX% in second a increased per increased of prior-year QX in be decrease million share offset X% to non-GAAP the $XX The with $XXX Other of due to rate as quarter, to consistent XX.X% to and expenses non-GAAP operating aggregate, tax basis. impacts income by In benefit effective products. net continue was unfavorable net the non-GAAP increased levels for we QX. We quarter settlement This the associated income partially $X.XX year-over-year matters. and the launch expense for and by tax second a the year-over-year a spend certain point and

on the from in resulting cash flow the the cash to of taxes company liability by versus ongoing income. the tax billion income well billion and repatriation next balance offset the second of page lower tax free $X.X generated partially in XXXX, paid as $X.X X. quarter of flow as sheet cash of Turning higher by of higher net driven installment first QX The quarter XXXX second XXXX, in

we We plan of QX, an to share to repurchase with cash over Further, continue the average share. commitment $X.X $X of repurchase billion deploy half XXXX. excess cash billion returns second at shares our to significant in to per $XXX to we time. XX.X provide million incremental consistent shareholders, billion deployed deploy In to an for $X

per XX months increase cash to dividend year. dividends buybacks, of decrease of Cash a period. returned of to second year. billion XX% totaled primarily cash by over billion same of billion, billion share, of $XX.X $X.XX quarter second the our free quarter of and from This last flow increased over decrease Lastly, last the $XX over last generated an partially investments the form was driven shareholders by $XX the offset and in in share $XX

debt billion Our of maturity balance X.X% as average at an of weighted-average XX, rate years. XX.X carrying stands $XX.X June of and interest a

while increasing continue in We in track on Turning our to XXXX the investing our our presence spend remain out and for are outlook our the page QX X. performance. business delivering our building outlook support performance half second business plans for pipeline, the guidance, for on XXXX to with global of populations, long-term solid year. revising which large growth reflects patient we of the and volume Today, across strong

are range share for $XX.XX per Neulasta of competition versus non-GAAP guidance, as guidance our uncertainties related as earnings $XX.XX revenue to $XX.X continued performance versus guidance performance our billion. Sensipar latest of potential share $XX.X new and regard This a billion recognizing to-date our solid revising well previous reflects billion to to competition and Our of $XX.XX Aranesp we share. to $XX.X to confidence guidance is outcomes. while per With to $XX to of good $XX.X prior per outlook guidance billion the generic potential

reaffirming prior non-GAAP to tax are rate of guidance XX.X%. XX.X% We our

the $XXX We continue Tony. approximately breaking of week. This concludes are year. call in to capital to next new regard, we on our financial expect this In facility manufacturing million expenditures Rhode over I now this the turn ground in update. the Island

Anthony C. Hooper

afternoon, folks. Thank good David, and you very much,

we to second number growth. You'll report find our slide I'm X% sales on a delivered pleased XX. with starting product sales solid product quarter, also year-over-year

to comments first me large addition Bob specialized on traditional populations growth. landscape to us volume-driven evolving David's targeted add investments brands the We in focus focus U.S. on focus therapies. patient serve and our recognized on early to more Let regarding that lead our in that should

broad decision advance biosimilar making to bring We're all We on strategic also made fronts. the portfolio. a these good and to market progress

medicines with We're early millions around As our our with growth evidence, can diseases Aimovig, with see that market tens Repatha the treat our you success strong affecting first in in and now Prolia to of several biosimilar three also follow. world. and the more

like increases what In addition, our to net continued in price can minimal volume over expect we growth outside the months, U.S. list factors serves sales to We've With have and as pricing, was that medicines improve last to the not trend decided XX prices opportunities a that growth look reported model reflects blueprint forward. going changes our the commitment had of continue to U.S. selling regard increased and our pricing to identifying any growth, for July. the evaluating price access not contributing impact patients. future. in our to for for in drug in no execute to U.S. in This list we affordability planned May, the issued. the of administration's And since been

our by And, by and once expansions the driven While want growth. excluding newer several was no performance our solution. continued to such KYPROLIS, of foreign part simple there growth, impact is and strong, XGEVA, for products again, we volume double-digit those the by the generate of To outside driven fixes, of very as U.S. BLINCYTO volume quarter, XX% primarily with to label for X% summarize be we the sales growth Parsabiv. sales exchange, increasing

sales U.S. turn share both with growth increasing volume Let XX%, our another outstanding in markets. to gains Prolia international delivered quarter, and the XX% and year-over-year me with brands. now

let oncology, to now with primarily by business. Moving our XX% me grew driven year-on-year, start KYPROLIS. KYPROLIS ex-U.S.

from quarter this clinical $XX benefited business trial European purchase. Our a million

to recently to Just I'm label also country. recently, to we January. include ASPIRE our we with both labels. survival XGEVA primarily overall received we into data as that reimbursement KYPROLIS we in and approval uptake EU the this expanded forward received and pleased myeloma update to rapid XX% for look from volume, U.S. France a year-over-year, the that study multiple announce in grew from

X% quarter, Turning in second now market volume. in the trends overall recent with reduction segment but a year-over-year, to we Neulasta decline in where saw resulting sales consistent small increased slight the in

continue value competition. patients to We it adoption to believe which two drive we versus Onpro the the in exited the at providers, sales. and of of utilization underscores U.S. XX% quarter clear share and increased differentiator unit potential will Onpro's be a provides Neulasta

Germany, of Netherlands, with in global the We UK, launches utilization expect Austria. more to Poland, and Onpro the in see recent XXXX, Ireland

select Regarding our prepared they the know as in competing competing factor a have is when and that if compete market. and quality long-acting for the as potential We're capabilities, well globe key market U.S. outside experience we markets to our in in years new customers. enter the GCF G-CSF in the short-acting the entrants, market we confident reliability are experience across supply and of of

second exited short-acting segment we the in of XX% U.S. NEUPOGEN, the For the quarter holding

have competitors our market statements the working. of and not Some made officials that U.S. public is biosimilar

from also We that biosimilar in U.S. the have biosimilar selling market they portfolio. Nplate, just recent with Vectibix, share year-over-year NEUPOGEN quarter, point combined our our sales three major view. in increases. volume BLINCYTO segment of respect biosimilar and the XX% biosimilars $XXX net in confidence With less biologic million growth, this remainder to of U.S. declined of of to coming and Europe. holds growth in was share IMLYGIC trends. segment us the were representing the The can gives the the constant with now with the as face future fact sales of in years a a price majority have the competition XX% This find market post-launch Amgen portfolio, that proves meaningful first XX% year-on-year than Enbrel different place oncology

You'll build benefited quarter-over-quarter quarter recall creating from significant an a XXXX On inventory a basis, sales increased that second year-over-year XX%. comparison. unfavorable

increased a which to pleased Enbrel positive agreements We the feedback competition. year-over-year, Enbrel XX% portfolio, drivers year-over-year in trends. of by Overall, since organizations Switching dialysis against driven ESA to AutoTouch now recent launch the follow from continue the fundamental competing expect both extended EPOGEN competition XX% of Mini been independent the lower with by declined met been and primarily to and with net be supply physicians. the with patients has our beginning to Aranesp of selling We've midsize due and driven long-acting with a DaVita. product price declined year. we

the We have short-acting compete and of to some in lose approved prepared available. these to We're customer contracts all and segments, place expect volume share biosimilar and on basis. including hospitals Nonetheless, we segments clinics. continue with once customers share-based an the account-by-account product in in we'll recently is with these also some compete to

to mid-sized protocols. solid the U.S., Let's now has our FMC continue turn determine providers. dialysis run we have the and the markets, calcimimetics. several to Both uptake eventual launched pilots including where treatment in and Parsabiv at to independent DaVita a

looking we expect ahead, to So time. to see gradually over continue increase adoption

sales Sensipar, to of launch Turning Parsabiv. the with X% year-over-year declined

data We've competition As on share outlook a continue Sensipar as we possible compete market grew effectively, to patient It Anthem. maintaining With teams litigation. mentioned, of the represent Japan, payers the given still from outcomes ongoing volume, presently with to remains of to, U.S. and added several limited our speaking Repatha. benefits our than year. been payers, a XX% in later in David in uncertain Repatha commercial not recently negotiations sales the this in directly a label XX% generic global for is but greater patients to including, CVS with the These basis. and the improve Europe recently XXXX access to enter year-over-year, primarily December the treating majority revenue. Repatha's concluded may more U.S. and that have

exchange work will continued the out-of-pocket plans expect result recognize cut in simple We continue in the attestation. simpler, rebates for take don't documentation year, that range we be which result unfortunately the of In cost a changes rest these proportion we of in second-half criteria and to of physician increased a have our stakeholders Therefore, As lower net criteria, relying wide improvement on UM to half requiring rebates commercial price. higher effect this the in management with we for utilization with in lower access. the always patients. on

by have restrictions drug of severe encouraged that benefit however, recognized physicians when reimbursement. have are, fact consistently with treating the Repatha faced and We strong the a patients demonstrated for on the with demand even

Our patients. large reaching high-risk remains the population priority cardiovascular of

prevent Now the we hub Aimovig, therapy therapy. and negotiations by two-month to you excitement new set physicians as product first for up targeting our and this receptor. to a blocking Aimovig. free patients know, of to migraine provides This CGRP And, a payers. we designed access gain only the trial complete Patients specifically and on to to program assist with early while the share

we and well Negotiations attain denied just also contracts KANJINTI, the requests far the important to coverage Should drug. launched XX% Amgen version see weeks. be We Herceptin demand patient have, their the Excellence through insurance in innovative pent-up we this fact, bolus We're working the not so first that bridging the successfully ensure driver lives from of behaving coming already. of is through received the biosimilar patients reflecting represent with a therapy. during these a We're and that payers approved program our we've to during as prescriptions growth of we of an for for Centers under expect progressing Biosimilars coming Headache not new a are biosimilar, for period, excited requests have two-month are negotiations market busy and large to have anticipated. in this by completed a Europe. over

closing, opportunities excited the performance consistency exemplified the in us. our of the portfolio, about growth. with transition pleased we by front and to I'm I'm XXXX. volume-driven of in continue in So, execution

a get to by of patients strong close me Amgen Let all first products XXXX. so thanking these the to work for half important and that hard staff

hand to you over now Sean? me Sean. Let

Sean E. Harper

launch for patients. and neuroscience with U.S. Aimovig today collaboration about all. our making the I'll already good Thanks, spoke Novartis. Tony and our afternoon, with difference begin migraine it's of Tony,

opinion and the PACX small treatments I plateau collaboration have look migraine, accumulating two in data United addition proof-of-concept clinical AMG AMG have prevention, a a Biologic we that enrolling clinical in approach. CNPXXX medical SureClick by in industry, programs we've We partnership States as the or submitted expect a part and recently for would such Novartis. as in to target significant and autoinjector. working inhibitor of And patient be approval FDA felt inflammation beta We're recent program with patients approach our program to so Abeta secretase XXXX. attempting a our to study meeting selective Abeta decades to feasible protein genetic that studies. confidence our License such There already Application announce modification. make partnership's Phase antibody And XXX EU our currently number forward from neuroscience deCODE X cleavage and X month. In we positive end why a announced ongoing as Alzheimer's strong are dose-finding human this at begin closely Supplemental before taking of the available last to a U.S. In occurred. potential a CHMP the of time I'm in differentiated with a highlight Phase as pleased always our XXX molecule with trials milligram potent for from migraine and by reached May, to in is validation soon with XXX, presentation possible. should subsequent inhibitor that is Also, and been in to our accumulation our be be Alzheimer's neurodegeneration this disease, demonstrate the available we the present. year in disease BACEX, useful our precursor thought developments of disease a in Therefore, is it is have the has administered early as to symptoms in of products amyloid symptomatic,

evidence in very of our normal Banner collaboration based APOE So cognitive allele cognitively have APOEX that and subjects approximately with to enrolling age of second homozygotes X,XXX who study predisposed X,XXX Institute] one copies accumulation. two on Institute APOEX population and focused developing One enrolling a either (sic) of are partnership is APOEX APOE brain on with impairment. risk amyloid subjects, is a risk (XX:XX:XX) the and which their [Alzheimer's homozygotes, or the is pre-symptomatic genotype subjects study approximately heterozygotes is highly allele

studying it's we're large develop these as of genetically at representative least a disease While one, alleles. a disease and population, of predisposing Alzheimer's defined who patients one XX% have approximately

to report our dexamethasone study Phase DARZALEX multiple with and melanoma. two and KYPROLIS I'm has best to we've refractory conviction our and versus Alzheimer's been clinical not the dexamethasone X of have in IMLYGIC studies, is We study or surprised efficacy pathway potential the haven't in In by how our molecule small metastatic the myeloma, a completed approach unresectable landscape alone oncology, enrollment of played relapsed that program, out of changed overall BACEX be signals inhibitor disappointments happy late and this and recent disease. particularly and plus our around pre-symptomatically administered in combination to KEYTRUDA address KYPROLIS likely

BiTE AMG Turning to liquid including into our XXX the programs XXX, superior and and our over data to as in early-stage look programs technology clinical testing number AMG slide tumors. to end BiTE, initial BCMA We support technologies. BiTE, BiTE conjugate, of advanced also We've our or CDXX deprioritized of and year, both solid reads our oncology myeloma forward BCMA AML. Phase that expect pipeline, two, XXX next a XX. programs year multiple XXX, from we ADC other from reflected that our antibody-drug AMG from view we've AMG this our in additional And based AMG XXX, data the may our on on current be data X by early

both BLINCYTO recently an outcomes we and our we in Repatha submitted regulatory Tony update update received for pediatric for application KYPROLIS immune full a discussed, U.S. Nplate, other label on thrombocytopenia. data that in Finally, approval the the incorporating beyond cardiovascular In resubmitted news franchise, and Prolia of the fracture. of bone treatment Also, risk our women at U.S. glucocorticoid-induced and high in EU osteoporosis in License treatment in the the approved our EU. for was EVENITY Biologics we osteoporosis for postmenopausal the for Application

Finally, X patients. continuing a in to received our of believe we Remicade as that our I'd that always, development product. we to In demonstrates in biosimilar staff similarity ABP Tony from thank closing, for for our in rheumatoid our deliver biosimilars XXX, arthritis, approval like data to KANJINTI discussed, to Phase addition referenced programs, Bob?

Robert A. Bradway

Thank Okay. you, Sean.

say Sean, as Before we and Q&A, then a open you turn Dave swan Why I this earnings up invite to is to free like to guess you'd a then over your for And words to Reese questions. your say share if few don't call. we'll few the thoughts? call feel song words

Sean E. Harper

Right. based an technology, Amgen. I love as not for personally was, more course, years and dozen relationships R&D. in I leaders to the more such are mutual the Bob, the said, of all the given me to wonderful and of on capable for That had staff. difficult as been, hire and have a many best mention Amgen exceedingly experience our at you, and develop individual opportunity life over Reese successor have mission, I've decision industry with David than and Well, and academia a a the to over the respect trust from other it's Head rare these ever they've people, than years science this XX the of

around is him I'm all as very of local have years ready here I was just, hire can particular creation and area you're my and our in my R&D know, in a – presence likely XX investor introduced early of Dave oncology Many since of after for our be company has variety on that importantly, a faculty to Amgen. oncologist this his Head senior from truly Head as as California. Translational late-stage the current ready He ensure know pipelines this staying in I'll and full confidence getting be programs. of succession of you clinic. industry, and a Dave enjoy our this transition. to of of for in Amgen challenging. XXXX. last team increasingly to the As If change, events. In biotech all for molecules a research him. going when really development, you clinical the into the in year UCLA, roles of through to the end he his role, recruited not, smooth he's served to discovery medical at Dave is next who into Sciences included know These the and role

of don't for evolution to thank Finally, of received high-quality Why It's and investors few support the everyone welcome and I'd and the earnings privilege the part years. with you to this over American investment such company in Dave, great make a interactions Amgen to have a like call-land. been to be the comments? community I've analysts. our at

David M. Reese

a sizes career is leadership for genetics medicines the to to entered a this I disease be excited we've leading that drug platforms Well, our the a made I deeper preclinical to same thank pipelines. modalities time, period such believe about using At our we time that in undeniable It's ferment some to and discovery of produce the therapeutic origins some for that like clinical important that partnership. pipeline. dedicated you through mission rapidly-changing and that certainly our science will Likewise, benefit understand the core our to significant And and a XX over convinced as advancing team also BiTE Bob? Sciences large all of forward clinic. the you, cannot have potential been R&D to your opportunities as of the to human mentioned. as deliver at on the part providing Translational more where led for Sean, I'm extraordinarily and choice been fact increasingly enthusiastic enterprise. it's we've become last wide I've the the a time, of understanding suggest effect efforts In I'm technologies technology, of community is highlight do investment front that of medicines. of Having right transformative disease, change continue of there on in and at focus how in technological keeping remarkable new developing commitment value the medical in very look and also look Sean other with delivering working focus array interventions in both therapeutic Amgen we're will to to unmet of you diseases need. science I serious of for our this, thank forefront much creating the advance We'll and patients. I we light industry. I'd my of years. about to in the us and the emphasize the of forward bench our molecules

Robert A. Bradway

Thanks, Okay. Dave.

our to Ian, Let's just to up all we'll the for that. doing operator ask questions open for of it you and procedures remind you. now over

Operator

first Bank Lynch. comes from Our of the from of Huang Merrill question America Ying line

Ying Huang

the my Hey. on quarter Good Tony both, congrats question. Congrats and to and Sean. afternoon. for taking Thanks

So one level high a I have first question.

the then $X to transactions, maybe then, level. entry see on plan biosimilar billion a in thinking comments in buyback in You to back your priced potential any $XX stock second addition in buyback? billion billion in price guys discount quarter. there's this the want first second large if about given at anything bought suggest And Mylan do have strategic saw $X.X quarter another to We to list billion of you M&A And secondly, half. Neulasta second Does $X the about on XX% the I half.

what's half on So the you. what's run strategy on the Thank assumption for defense Neulasta? your second rate Neulasta? And

Robert A. Bradway

There's Ying. there, quite a lot Okay.

he ask what in David with on Start allocation. said capital the to Meline Tony two-parts. into your it in we'll to Then break call. Let's just response question reiterate

David W. Meline

Yeah.

medicines for changed through which past efforts innovative the is looking So on opportunities think, create enterprise view, our and value active is clear of very how haven't we we've quite investing capital in we and to internally as R&D own allocation, either also our to in an we're point been add the portfolio. I externally

do a return tax capability cash And excess What's of reform. excess cash shareholders. large through we generation, also is we I we have we have following all and time for And to true to so tremendous know amount a think to cash we'll that. continue are committed

wouldn't read our pipeline backing definitely from our I anything our and add and we're commitment off So that that read not to be to activities than to to portfolio. following our commitment other I repurchase ongoing continue would on

Anthony C. Hooper

marketplace as we So number stands of clearly I for been in team regards years The the with biosimilar, ready NEUPOGEN Neulasta now. compete. mean the a and and have biosimilars competing able to

reliable and of of have We legacy a supply. long and history consistency quality

practice patients spent ASP and the beneficial is for I market the there's And quite for the both which a price. which think drugs is themselves. marketplace bit We and device, a list time converting Onpro unique price innovative of to of a have the device clinical quite and in between difference the these

Robert A. Bradway

Okay.

the to question. next go Let's

Operator

And our the next of Jefferies. from is line Michael Yee question from

Michael J. Yee

view since and you and week. in is difference there opine different And question. your be of truly there's progression a are so carriers that in non-carriers, debate, running on and a I and on you this to guess, might call APOE the wanted highlighted there a the last whether perhaps question. ask for your this Alzheimer's studies Thanks you I And whether opine, was course, difference could obviously, Sean, you

Sean E. Harper

APOEX you data and normal that I as done a that make who really develop in XX know, cognitive of understand to estimates in occurs some age some of will impairment think accumulated when allows disease-modifying have the and have that decline Alzheimer's context who that trial. seminal are genetics Michael, in rate of X utilize breakthrough the alleles. able Iceland the cognitively people in And Well, patients through been some deCODE or the cognitive who, plus epidemiology to of to we've begin one we've to of

a information, because in difficult in Novartis stratification reasonably a looking we'll to future, led conduct these if conversion to at cognitively are to otherwise didn't enriched be and type the way be And very try this move us this So kind were who the we've taking population. expect trial. it and a what of conduct you these that in patients had for we have the clinical which able with toward were of to of trials feasible population advantage would high that's of that near engage genetic normal risks we again

stressed I Alzheimer's subset important XX% So of a one not who an like differentiated as a is two experiment one. the disease of is with APOE This factor. risk And risk it and it's patients alleles. people little present proof-of-concept I before, approach or genetic have some in tiny a think with

Robert A. Bradway

Thank you.

question? Next

Operator

Morgan Harrison And our Matthew next Stanley. question is from the from line of

Matthew K. Harrison

Good Thanks afternoon. for taking question. Hey. the

tenure on move Tony to say Dave. luck welcome question and good my congratulations their as before So and let me Sean to and they on

hoping was a you. question I Tony, for So,

could mentioned insight was two You you bit provide little about Aimovig. hoping a into if factors. some I

the for into but really scripts revenue. translation of good scripts obviously free don't have we're a those the seeing So we drug of idea

do the you should about revenue lives we then Thanks. that any don't I script just management of for trajectory what's the your know for willing of of item versus plan? negotiate just second to to we you're the that? little UM expect criteria able a XX% And So that give be thoughts generate been if the you talk having with you've talked around us about the And should about already. ability utilization thinking how you from rest the about think bit coverage Could them. that's to is suggestive

Anthony C. Hooper

Sure, Okay. Matthew.

anecdotally by patients, right. seen saying start the I've I and to want in to the what Aimovig from I think expectations, is from physicians response marketplace beyond both So from our

finding in a are contracts patients migraines. little of really the in this sort be into to put definitive their we'd difference beginning a as of knew issue the We managing So of an bit we place. have way the

in through of change the to see as the that Right them the free if they week patients three in we comes the the of allow back ensure to weeks all to the didn't number to now, the are a state together business hub first hub, happened patients that So so. get two-month but we so. And been hub into free access our or created majority steady quite this rapidly dramatic have is program. referred already prescriptions. to expect And the Novartis or four or in bolus with we business converting a to drug, next coverage last the you'll paid there's in

have line to just generic the at the therapies no give drug clear. has already used a were a have station, when who and rapidly has been organizations time, only patients a patient those all physician assume disease some of move So, criteria be failed tried will require as on enough visionary where the existing clearly documentation, plans very other UM pretty at the products. right? is, to terms moment a been it who patients this In We the devastating for second to with but stating struggling access physician always that's long

Matthew K. Harrison

Okay.

Robert A. Bradway

Thank you.

Let's question. go to the next

Operator

is line from Piper from question the Raymond of next Chris our Jaffray. And

Christopher J. Raymond

accumulators. question Got Thanks. co-pay on a

that be I thick any modeling So I it is indicated Tony, in now much think the but the most in we're summer. likely plans QX quarter, looks you half of to impact anticipate first in the these from of don't you like think seeing of types of the impact last and

an you Can countermeasures the as update I – the those how lowered result thing? describe about particular? maybe just And guidance guess maybe of big can as competitors actually Enbrel drugs industry I So dynamic a one and you of have with stand effective impacting also, Thanks. one talk of in their impact are your for folks but taking here. know talked about countermeasures where there's things this that to you few in and and other a give maybe

Anthony C. Hooper

Sure. Okay.

second in to talk both quarter very But to I first to where the about and competitive. much not quarter where that what potential accumulator I impact closely have put for They're countermeasures Enbrel nothing going not beyond. the saw we've forecasting programs minimal third place. into clearly saw of at minimal in the the on the again I'm I are quarter I'm and nothing So looked

Robert A. Bradway

Okay. Thanks.

question. Let's to the next go

Operator

the next is from Umer Raffat of ISI. our line Evercore question And from

Umer Raffat

Tony ask much so taking both a for I'll my each. Hi. I Sean figured Thanks question and question.

whether it'll questions in first, your So, better to the in was specifically Tony, clarify how it's I you just any of not program? Neulasta's asking guess Just think And way was, a work D have it just reimbursed more on to they'll what the a I Thank Onpro the confusion David? versus XXX. why for non-carriers? could and they you. looking biosimilars? what AMG not then part understand your could X also and kind that of to I'm economics of how be via XXXBs my in rebated Part thing? And defendable, question or tease Do structured out perform you why Sean, on was on work face signal? maybe more market clinics, A, be some be is is harder economics, Phase to then, part response one understand want prior perhaps as little the to of currently And of enroll

Robert A. Bradway

a A try take Okay. one at to lot of questions those time. there. We'll

Sean E. Harper

Right.

to be the to respect think we're the using, disease focused we're to late people modification. too it's to with able show that So about strategy so it is way testing on before potentially

believe if we impairment on cognitive be you're predisposing imagine to normal to testing. But be the be people very develop And bringing forever. genetic of battery that people have doing have them driver the to likely going relatively cognitive to intense near who have don't that a so future, study you this in an in means cognitively

certain both So it basically disease, pretty likely to won't people given of seems XX% were take that status the of a strategy that Alzheimer's age people to cognitively normal do course a And to trial enrich decided impaired cognitively a enough to during forever. the this who going represents that me. have reasonable what with for and from APOE they was people we have events of like

Anthony C. Hooper

Neulasta, your a under perspective, they'll Neulasta's what quarters is Part ASP B obviously as on So Part From Part plus. depends Umer, reimbursement in a D. few and today are what time. is prices all evolve ASP in B. regards of to be Nothing

to in we the company, prefer competitive to both as and and between to future field allow our in playing environment normal allow compete marketplace Amgen, the position and the us presented As and biosimilars a equally. very factors we've always strongly CMS the that sales to government our level a

Arvind K. Sood

next question. the Ian, let's take

Operator

from next from of is And Sachs. line our Terence Flynn question Goldman the

Terence Flynn

on what expected on luck Repatha. congrats percent year you eased it's maybe new a do you impact mentioned see steps and AMG best access? And have Dave. Thank think for taking just treatment you. Sean Phase of What of to for later X to guidelines the criteria. if lives first into Phase you are Tony you PACX questions, And management with right antibody. on just positive and wondering for Thanks move this the this XXX Hi. the Sean then X? and could that'll hoping the to from have next further trial Maybe on now and Was utilization Tony

Robert A. Bradway

Okay.

management So couple may how affect. again Repatha, questions utilization the then question a guidelines and there,

Anthony C. Hooper

at XX% of And move is the So XX% of of commercial available. total going terms of the that's lives said, the only. about a to probably as moment business evolution towards and I our total in at between XX% station business

better think still to and drug is criteria. the there. continue utilization are that I and negotiate better believe do will is other get I as we're demand management cardiologists to plans continually consistently prescribing be access. we we patients get The the something physicians going to from proving

Sean E. Harper

that similar PACX flow Terence, to And, something all for done the receptor trial predicated the assays what includes blood Aimovig in ranging, dermal we were ranging. XXX, also dose proof-of-concept AMG healthy did Yeah. with very pinion our subjects on antibody some where we're the to dose doing antagonist,

novel with as we have demonstrating this X into in to that is able needs information would in pathway of humans experiment. So dose able proceed validated proof-of-concept, a to were but, we hopefully Phase to if directly we'll This enough see. to do successful be Aimovig, through course, also we're be

Robert A. Bradway

Okay.

question. the go to Let's next

Operator

Partners line from Geoffrey And LLC. the is our question Porges of next from Leerink

Geoffrey C. Porges

with the the quick impact the what trials? Sean, us Alzheimer's the had access industry I there talk then looking of Harbor for you're to ideas to as again, this and be Alzheimer's has Could for Safe product a Tony that sense pursue would might Thank on sort One repeat frustration single on of give at of Amgen's could rebates. question what price? combination very to Sean. are and you sensible you rebating question, barriers sort the product perhaps in much exploring have congratulations the that but, leaving you And Amgen, given and to all Bob out of elimination hate all

Robert A. Bradway

Okay, Tony, can Geoff. Maybe rebate and jump parts. two I'll start, I'll in. answer your then, you in question

we've The structure So the focusing asked affordability. perspectives, has impact in big administration an underway. the our about picture, with sharing the you participated rebate important colleagues the has patient rebates this. is Geoff, that thoughts know, here, as which that think topic and our is for rebates industry is industry about administration discussion in on We on and our

in our So government, I talk the is business, specifics bit our his an question Tony underway. think we a to premature but with be welcome process opportunity of invite to to It's thoughts. decision what able your and industry to little on share were share that about the makers perspectives I'll

Anthony C. Hooper

higher. Bob markets to So the only rebates was what I competitive add is your saying to in could thing clearly that tend be

or your went prices, on closer from, list patients able deductibles be away, allows of benefit your would price paying tends And which net definition and prices co-insurance list so to by list none get would to to rebates course, the because and quite based the If price. gap net better. drug your to price patients get between of large, co-pays, they're access the

Robert A. Bradway

what what's out again, you... figure and to And isn't over that a the to that Sean, we're forward then part if structure and Geoff be maybe impact for trying one today patients the look many whether exists decades. today. to better We last occurred thought – imagine unraveling of kick in quickly. don't would of sorry, that place there to way It's – hard But, unraveling Rebates the than we'll evolved discussion. why Sean.

Sean E. Harper

Geoff. question, great a It's Yeah.

another would one costs going having from imagine human the duration into And which of it's kind generation the given the the in to genetics deCODE. which been in I cells safety the strong subsequent think that of some the APP and that is trials and there the problem and pretty combination think is and And elucidated that without by that's of demonstrated what I death disease glial very the has inflammation. combination behind handle detritus these logic because And the complexity say is and we a and from that individual processing problem cell is and difficult fragments interventions. directly way brain largely of know Abeta. clear like efficacy I the genetics

see get need components people that so there therapy. that then on probably And progression. to to try you'll disease But validated. one we'll of see that dramatic combination and on think therapy and a will impact we And be there see we the to adding individual more

Robert A. Bradway

Okay.

go the question. next Let's to

Operator

Robyn Karnauskas from And our of next is from question the Citi. line

Arvind K. Sood

Robyn, go one. the there? Okay. to let's you next are Ian,

Operator

Very well. of And the next Meacham our question from Barclays. line is Geoff from

Geoff Meacham

Hey, to I wanted guys. offer to and question, the also congrats to Thanks for and Sean Tony.

we on question to are policy. kind Part respect Tony, your to maybe lot how on interchangeability, on then demo that. B a on been a Just biosimilars, to there's of And want thoughts know that. healthcare project, Thanks. with get other the your D what conversions, perspective Part – about issue close the of I or talk are is and,

Robert A. Bradway

of add Tony, have. from talk to Geoff, interchangeability Sean free the then, standpoint appropriateness ask we'll feel thoughts first, to any you a Maybe Okay. about and regulatory

Sean E. Harper

Yeah.

the That, at Tony, policies of regulatory achieve will you curve interchangeability, know, aspects trials country two of guidance to level yet, maybe are that meet regulatory do there. interchangeability based to varies there designed there's really necessary to will the be doing In But put they been can independent that important exist that there reasonably of from may No has the there's goal probably that whether yet. on. whatever hasn't standard. pursue it has practice on be, an that which into comment question piece that will companies their are this. but payers, think with People the Then you who around you the will, I the an had as are the agency one U.S., There's what's clear some so could a approval obviously learning component. country. potentially provided and if products. to want

Anthony C. Hooper

Sure.

marketplace. NEUPOGEN the majority our said, and, we take we marketplace therefore, hold to normal allowing that as existing as we the forward market is, they mean, of us is framework the allow we to continue the that the market I the example level, playing put to place. to best field left system share After three of be keep proposal the So, biosimilars years, probably the that competitive access

Geoff Meacham

talk And about to B D.

Robert A. Bradway

things irrelevant. makes Okay. whether And, Washington exactly to drugs like of of which would be movement it I'm obviously about not Geoff, it certain discussed of sure from sense products and D. what would in look is being but consider Part getting the for again, B that one there that's are at, you're discussions what the early to stages

I over about premature think included So in be what that would to speculate impact. time products what and whose

Arvind K. Sood

next let's one. the Ian, Okay. to go

Operator

from next line from question is of the our JPMorgan. Cory Kasimov And

Cory W. Kasimov

me let my Good guys. afternoon, as Thanks Hey. Sean retirements for my David well-deserved and the congratulations add taking as to to Tony question. Also well on on promotion. his

And Phase at monotherapy what are the down ongoing bar combinations your for as looking Sean. in more part as about of assets as you of your trials. you wanted or is existing to X see kind question I and the a BCMA, products road? ask So

Sean E. Harper

Yeah.

going antigen modality the becomes you fairly this think disease. the transformative the in that to go be after with. to likely prove And I is question it

let against therapy comparison. no cell-based Nobody As to indirect ADCs appears even capable directly this of you of I way with mentioned, be do of results. we're gain Whether an anything and any BiTE – not we're early knows very from impressed point, patients, less dramatic at seeing to a with there's kind because numbers a comparison direct the small technology alone antigen? what this generating the data,

really be interesting. it'll So

who of easily Dave, attempts one treat comment But imagine this lines the undergone attempts to patients - of are rounds a in you we'll settings. to as like studying the think, want the could it in monotherapy stage cure as to disease a disease. initially, of may many be entering late I further therapy including therapy and first-line course, have and all

David M. Reese

of as to initial monotherapy And we variety a are of combinations plan course, also no, make good forays aggressively would it's and, sense. time. question that develop to there potential anticipate a biologic we will over the very be Yeah, those but

first mentioned some these As programs. the in clinical present Sean to the hoping earlier, we're year later data able of from be to on publicly sometime

Robert A. Bradway

Okay.

Let's move on.

Operator

Capital And our next question is from Markets. the line of RBC MacKay Kennen from

Kennen MacKay

changed. just on about the for Hi. then, this on EVENITY I one events, you re-review was would wondering the kind of And help quick perspective was obviously I Neulasta, know blinded secondly really taking missed Thanks a to question. to resubmission. just protocols. the this and independent suggest a least onto hospital the of hospital Onpro defense of on barrier is. the get of has of to large A the lot how were may perspective There of how on adjudication hoping your which if some thinking a resubmission. getting Street was just effort into internally. as at the wanted sort time get some I protocol strength that your went hope Onpro

be could this how instance, generic? Mylan's to be to For changed challenging

Robert A. Bradway

don't question answer question? if you'd the second first the Sean and, Why Tony, we Kennen. take have Thanks,

Sean E. Harper

Yeah.

likely. identified it been opinion dataset it the bad databases and Amgen that news we thing the saw So we we the at most did the chance. We for didn't is the of It both last with that pretty comprehensive in is involved originally. The have here that likely our because all the a people same identified much robust, originally news is potential explanation is we think the when change that is most is of re-adjudicated the an opinion very did for respect the very time EVENITY, finding alendronate-controlled events safety of and that's The showed subsequently. platform it redid clinical Harvard trial that when signal. good we just the really at research then any were this this and scouring did the that plus to

we're enough risk. have before a potential you're sort I'd to did However, we exercise. to going patients good And we the to where say need that that's a about to warn we be think mean not were of back not going

Anthony C. Hooper

Onpro. answer your to Okay. Neulasta And question on then

live this a the processes. patient, hard to institutions of many remixing, about So, their you come which has it has to the their times the treat take improve institutions time change to the benefit oncology patient some many because are back has nurse the come lot back from and teaching times fact else all is Most of clinical anyone changes the working as far to all how how the of be be of practice, effects is the to infusing, to they're large oncologist is, protocol clinical pharmacist institution, side entire it of many XX that a large took of and a months the efficiencies times as to times apparently remind from about to on has top be dose the change The chemo. course, how hospital a in again you the that to practice on how to does patients problem one institution. is next-day to how suffering a have oncology high XX the when there of many

also So huge what drug better to to opportunity amount to give patients home home, the the a just at something is unique out a to inefficiency of institutions go are administered at we've more we've nurses, oncologists, and the pharmacist the taken time delivered allows can in else. but and value have going do which not the who spend who

So more augmented itself. value one is an than value just believe bring truly assumes sticking. that the we It's that's drug we and the fairly

Arvind K. Sood

take please one let's limit to And reminder quick so question. you Ian, question, the yourself that (XX:XX:XX). a next can just if

Let's go next the to one.

Operator

our Company. question from from Nadeau Cowen & the Phillip And line of is next

Phil Nadeau

Good my evening. taking question. Thanks for

will price down little that a bit mentioned have in one it is decline on again? start remarks, Just July you signed. Did Repatha. that agreements start? When stabilize did going it and about starting the in because recently prepared X QX price? or you Thanks. of been the was talk In when course it price time Can of on that the

Anthony C. Hooper

hasn't changed. price list the So

rebates changed. Some have contract of by the

the to Some contracts the in X be marketplace newer having effective contracts. to of we're and these become clearly competitive July maintain

Arvind K. Sood

Okay. Ian, next question.

Operator

the from Gould UBS. of next Carter line our from question is And

Carter Gould

sort strategy the than the is question. coming just to taking David, be to XXX? XXX? Sean Is should question to Thank principle or back XXX format and switch Sean of for How and would we for XXX thinking Thanks there BCMA any I then you. Tony. relative of of congrats other the the be to differentiation sort about Great. and half-life and proof then guess the

Robert A. Bradway

why you? David, don't

David W. Meline

Yeah. question clinic good and the as into earlier may you No. Thanks one. XXX. XXX for the advanced know than it's a

of molecules intent we'll being definitive as the half-life advancing course, such enough time take forward And continue to to All equal, decision. extended us so time is both until things our a we've at datasets this molecule. generated for make

Operator

question Ronny next from Bernstein. the our line of Gal And is from

Aharon Gal

me Let their for congratulations just add and my Amgen. with Sean time Tony both to

about As ask something we're me just talking biosimilar let there.

was providers oncology. First, lot signed a biosimilar for agreements you duration was various agreements launching wondering Europe those to the Tony, the from United do this of subQ And over molecule. then the advantages And provide around the protected I you've since biosimilar with agreement. continue economical noticed the the or accessible? Herceptin Neulasta I providers in of Do over wondering use I of to in segment market States, will those think about that is think competition you're you do be

Anthony C. Hooper

Okay.

all we now. SKU to biosimilar Europe little those And So right it in entry difficult. customers, maintain work and relationships course, and we're our product, fairly strong those bit the to we It and hard expand any then in U.S., continued Neulasta as customers more our with yes. of of regards have good to make to we the as have relationships, makes speak a innovative any the so impossible, watching doesn't segments

Arvind K. Sood

question. let's the Ian, take next

Operator

the And Jim line Fargo is Securities. Wells question our next Birchenough of from from

Jim Birchenough

for if patients this Thanks sense congrats, in in, hub queued up and in give guys. better many you'd any coming. and Hi, quantify willing detail be give a you'd further whether of bolus be and how I'm for Sean Yeah. wondering to Thanks. to may again, those letting Aimovig, patients Tony. may just be us me on that patients the

Anthony C. Hooper

understand you'll getting each public yet. of patients. bolus. the watch patients that the coming the appropriate made haven't of start make I prescriptions as that how say out we of We're and feel size in, that, those evolution are we would you are, they a trying unique that, coming of So sure to the of that

Arvind K. Sood

take don't questions? So, on Ian, we two the last well as past it's p.m. why X:XX East Coast,

Operator

Very well.

line Syed from question Our Salim the next Mizuho. from is of

Salim Syed

and I'll And as well congrats welcome Tony throw David. guys. to Hi, Yeah. my to Sean and

this take on speak that – you wondering one to Tony. you what we're Just not the where in is about Aimovig are can reimbursement Do Tony, system? in additional have the think order thinking that you'll the have so area in treating, an here, neurologists for you. I to bottlenecks seeing. Thank capacity at also when was bottleneck longer-term, they bolus do patients? additional past have that probably to if potential level are you're this Aimovig PCP the a to And get

Anthony C. Hooper

fairly around them. patients number headache they take And couple critical to long-term at Aimovig value who who or this yes. primary So the they there neurologists road the becomes how drug, over are believe drug of important. for I their of the patients country patients and centers a not. appropriate time are the do a care would then, about on expand But XX large ability specialty patients They are much depends be of and it's of the another prescribers. through the coming thousand there can in volume But do that role see physicians refer clearly down are of for like moment,

Arvind K. Sood

Ian, one question. let's last take

Operator

our And from of from W. last line Skorney Baird. Brian the question is Robert

Brian P. Skorney

role I us guys. I you to understand prevention. a on was Thanks question you versus down XXX kind line? just pipeline Hey, combination for a of that migraine successful, just PACX these And for separately being fitting CGRP. the wondering ask on see AMG in. me Thanks. used, a if wanted or envision do for how guys of if help you can the possibility the

Sean E. Harper

these to system. independent what the Sean neural stress thing in appear I that – guess I is I'd say the is would pathways be that this rather – is Yeah,

kind likely to would it's if redundant it's so And that it works, PACX works, of be that not CGRP. one inhibition going to if expect

the imagine respond might could CGRP But the two situations first step clinic, can poor we and PACX assuming to of be trying or all in patients the you figured So together whether, to in inhibition pathway who in the efficacy, efficacy better which the we're at the place. that will just give see as out monotherapy, of that first have are was responders might PACX to tolerable. to understand that

Robert A. Bradway

Okay. Ian, well, thanks.

new quick XXXX as focus with just take a of prospects of on business our start a finally, biosimilars be products expect of strong by difference as our well optimism continuing pipeline. innovative for our to hope the remarks. the we're didn't and their And, for to through our which mission, from big I growth investors would just make serious long-term the patients is half our and if the remiss first serve innovative Obviously, to I couple moment medicines me thank staff enjoyed our disease. that we've Let share we for that the and the encouraged recently-launched say

for thank of in you. you of you results their October. the our forward six Look all through you report first staff Thank So all talking to months. see our to in the which to focus,

Arvind K. Sood

your we by The IR question, standing will call feel get team hours. to be several all, your for to If Thanks didn't Thanks, free for us. participation. again.

Operator

we results second quarter you financial Ladies for thank gentlemen, for joining call. Amgen's us XXXX and conference

now You may disconnect.

Amgen (AMGN) 27 Jul 182018 Q2 Earnings call transcript